Joost Boormans

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4850268/publications.pdf

Version: 2024-02-01

95 papers	3,520 citations	172207 29 h-index	149479 56 g-index
97 all docs	97 docs citations	97 times ranked	4287 citing authors

#	Article	IF	Citations
1	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. Journal of Clinical Pathology, 2023, 76, 126-132.	1.0	7
2	Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 62.e13-62.e20.	0.8	21
3	Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. European Urology Focus, 2022, 8, 995-1002.	1.6	6
4	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. Journal of Urology, 2022, 207, 541-550.	0.2	30
5	Antiâ€“PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. Clinical Cancer Research, 2022, 28, 215-226.	3.2	5
6	Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 331-336.	0.9	23
7	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	0.8	22
8	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	1.7	1
9	Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ESMO Open, 2022, 7, 100416.	2.0	10
10	A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice. European Urology Open Science, 2022, 39, 7-13.	0.2	3
11	Optimization of Preoperative Lymph Node Staging in Patients with Muscle-Invasive Bladder Cancer Using Radiomics on Computed Tomography. Journal of Personalized Medicine, 2022, 12, 726.	1.1	2
12	Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review. European Urology Oncology, 2021, 4, 204-214.	2.6	20
13	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. International Journal of Cancer, 2021, 148, 981-987.	2.3	12
14	Hospital volume is associated with postoperative mortality after radical cystectomy for treatment of bladder cancer. BJU International, 2021, 128, 511-518.	1.3	4
15	Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-GuÃ©rin: Extended follow-up of KEYNOTE-057 cohort A.. Journal of Clinical Oncology, 2021, 39, 451-451.	0.8	5
16	T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-GuÃ©rin Failure and Improves Patient Stratification at Diagnosis. Journal of Urology, 2021, 205, 701-708.	0.2	20
17	Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the â€˜trials within cohortsâ€™ study ProBCI. BMJ Open, 2021, 11, e047256.	0.8	5
18	Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study. European Urology, 2021, 79, 609-618.	0.9	32

#	Article	IF	Citations
19	Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 4523-4523.	0.8	2
20	Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch populationâ€based study from 1993 to 2017. BJU International, 2021, 128, 343-351.	1.3	23
21	Gene Expression Profiling of Muscle-Invasive Bladder Cancer With Secondary Variant Histology. American Journal of Clinical Pathology, 2021, 156, 895-905.	0.4	5
22	Abstract 615: Differential pathway analyses of BCG-treated T1HG bladder cancer using Philips OncoSignal: A pilot study. , 2021, , .		0
23	Abstract 2190: Integrative genomic and transcriptomic characterization of metastatic urothelial carcinoma. , 2021, , .		0
24	Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 919-930.	5.1	239
25	Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European Urology, 2021, 80, 4-6.	0.9	6
26	Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 60.e1-60.e1.	0.8	4
27	Risk factors associated with positive surgical marginsâ€™ location at radical cystectomy and their impact on bladder cancer survival. World Journal of Urology, 2021, 39, 4363-4371.	1.2	22
28	New horizons in bladder cancer research. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 867-885.	0.8	7
29	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€"An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
30	Cationic amphiphilic drugs as potential anticancer therapy for bladder cancer. Molecular Oncology, 2020, 14, 3121-3134.	2.1	6
31	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	0.9	57
32	Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. Cancer Treatment and Research Communications, 2020, 25, 100266.	0.7	10
33	Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions. Applied Sciences (Switzerland), 2020, 10, 7102.	1.3	5
34	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 701-710.	0.9	128
35	Outcomes of urinary diversion after surgery for locally advanced or locally recurrent rectal cancer with complete cystectomy; ileal and colon conduit. European Journal of Surgical Oncology, 2020, 46, 1160-1166.	0.5	4
36	Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: Are they clonally related? A systematic review. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 590-598.	0.8	30

#	Article	IF	Citations
37	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology, 2020, 3, 420-423.	2.6	29
38	A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy. Journal of Urology, 2020, 204, 50-57.	0.2	11
39	Early response marker during pembrolizumab treatment in metastatic urothelial cancer: Temporal shift in peripheral CD4 T cells expressing chemokine receptors.. Journal of Clinical Oncology, 2020, 38, 5033-5033.	0.8	2
40	Open versus minimal invasive radical cystectomy. Translational Andrology and Urology, 2020, 9, 2471-2473.	0.6	0
41	Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2020, 38, 533-533.	0.8	0
42	Reply by Authors. Journal of Urology, 2020, 204, 57-57.	0.2	0
43	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	1.2	31
44	Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guÃ©rin (BCG). Annals of Oncology, 2019, 30, v364-v365.	0.6	4
45	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Medicine, 2019, 11, 60.	3.6	36
46	Bladder cancer survival: Women only fare worse in the first two years after diagnosis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 853-861.	0.8	14
47	Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clinical Cancer Research, 2019, 25, 3908-3920.	3.2	71
48	Challenges of urine-based molecular assays for the detection of urothelial cancer. Translational Andrology and Urology, 2019, 8, S493-S496.	0.6	3
49	EAUâ€“ESMO consensus statements on the management of advanced and variant bladder cancerâ€”an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	0.6	96
50	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 5082-5093.	3.2	82
51	Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3â€4aN0M0 compared to cT2N0M0 bladder cancer. International Journal of Cancer, 2019, 144, 1453-1459.	2.3	26
52	Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonâ€“muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-GuÃ©rin (BCG): Updated follow-up from KEYNOTE-057.. Journal of Clinical Oncology, 2019, 37, 4530-4530.	0.8	4
53	Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guÃ©rin (BCG).. Journal of Clinical Oncology, 2019, 37, 350-350.	0.8	103
54	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 423-431.	0.8	16

#	Article	IF	Citations
55	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2018, 122, 978-985.	1.3	25
56	Molecular Markers Increase Precision of the European Association of Urology Nonâ€“Muscle-Invasive Bladder Cancer Progression Risk Groups. Clinical Cancer Research, 2018, 24, 1586-1593.	3.2	79
57	Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial. Contemporary Clinical Trials Communications, 2018, 9, 121-129.	0.5	16
58	Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies. International Journal of Hyperthermia, 2018, 34, 407-414.	1.1	20
59	Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. European Urology, 2018, 73, 394-405.	0.9	78
60	Reply to Nelson Martinez Merizalde Balarezo, Mark Monroe Rivera, and Romina A. Tejada's Letter to the Editor re: Maud Rijnders, Ronald de Wit, Joost L. Boormans, Martijn P.J. Lolkema, Astrid A.M. van der Veldt. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017;72:411â€“23. Beyond the Survival Rate, Health-related Quality of Life is Important. European Urology, 2018, 73, e67-e68.	0.9	0
61	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. Bladder Cancer, 2018, 4, 395-401.	0.2	55
62	Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder. PLoS ONE, 2018, 13, e0209101.	1.1	7
63	Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 361.e7-361.e13.	0.8	20
64	Total pelvic exenteration for locally advanced and locally recurrent rectal cancer in the elderly. European Journal of Surgical Oncology, 2018, 44, 1548-1554.	0.5	16
65	Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology, 2018, 73, 983-989.	1.6	24
66	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology, 2017, 72, 544-554.	0.9	638
67	Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. Scientific Reports, 2017, 7, 2374.	1.6	30
68	FGFR3 , TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. Journal of Urology, 2017, 197, 1410-1418.	0.2	70
69	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. European Urology, 2017, 72, 411-423.	0.9	89
70	Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy. Journal of Urology, 2017, 197, 590-595.	0.2	102
71	Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2017, 35, 281-281.	0.8	7
72	A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable. PLoS ONE, 2017, 12, e0174039.	1.1	7

#	Article	IF	Citations
73	Limited Funds for Bladder Cancer Research and What Can We Do About It. Bladder Cancer, 2016, 2, 49-51.	0.2	25
74	Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity?. Brachytherapy, 2016, 15, 707-713.	0.2	5
75	Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome inÂPatients Undergoing Pre-Operative Chemotherapy inÂMuscle-Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 351-360.	0.2	24
76	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 469-476.	0.8	8
77	Attenuated XPC Expression Is Not Associated with Impaired DNA Repair in Bladder Cancer. PLoS ONE, 2015, 10, e0126029.	1.1	10
78	Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. Radiotherapy and Oncology, 2015, 117, 252-257.	0.3	18
79	Targeted therapies in bladder cancer: an overview of in vivo research. Nature Reviews Urology, 2015, 12, 681-694.	1.9	63
80	ETS fusion genes in prostate cancer. Endocrine-Related Cancer, 2014, 21, R143-R152.	1.6	83
81	Bladder Function Preservation With Brachytherapy, External Beam Radiation Therapy, and Limited Surger in Bladder Cancer Patients: Long-Term Results. International Journal of Radiation Oncology Biology Physics, 2014, 88, 611-617.	0.4	24
82	A 36-gene Signature Predicts Clinical Progression in a Subgroup of ERG-positive Prostate Cancers. European Urology, 2013, 64, 941-950.	0.9	31
83	Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. International Journal of Cancer, 2013, 133, 335-345.	2.3	59
84	Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 149-156.	1.4	9
85	Confirmation of the Association of TMPRSS2(exon 0):ERG Expression and a Favorable Prognosis of Primary Prostate Cancer. European Urology, 2011, 60, 183-184.	0.9	19
86	No evidence of FGFR3 mutations in prostate cancer. Prostate, 2011, 71, 637-641.	1.2	4
87	Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Modern Pathology, 2011, 24, 1128-1138.	2.9	106
88	Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG Does Not Predict Response to Endocrine Treatment in Hormone-NaÃ¯ve, Node-Positive Prostate Cancer. European Urology, 2010, 57, 830-835.	0.9	31
89	Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer. Clinical Cancer Research, 2009, 15, 6398-6403.	3.2	81
90	An activating mutation in AKT1 in human prostate cancer. International Journal of Cancer, 2008, 123, 2725-2726.	2.3	17

#	Article	IF	Citations
91	Histopathological characteristics of lymph node metastases predict cancerâ€specific survival in nodeâ€positive prostate cancer. BJU International, 2008, 102, 1589-1593.	1.3	44
92	Truncated ETV1, Fused to Novel Tissue-Specific Genes, and Full-Length ETV1 in Prostate Cancer. Cancer Research, 2008, 68, 7541-7549.	0.4	86
93	Invasively Estimated International Continence Society Obstruction Classification Versus Noninvasively Assessed Bladder Outlet Obstruction Probability in Treatment Recommendation for LUTS Suggestive of BPH. Urology, 2007, 69, 485-490.	0.5	6
94	Re: Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers. European Urology, 2007, 52, 1529.	0.9	1
95	Percutaneous nephrolithotomy for treating renal calculi in children. BJU International, 2005, 95, 631-634.	1.3	40